 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has entered into a Stock Purchase Agreement with Syntone Ventures LLC for a private placement of 16.0 million of common stock at a price of 1.00 per share. In addition, Outlook Therapeutics entered into a joint venture agreement with Syntone Technologies Group Co. Ltd. Syntone to form a PRC joint venture to develop and commercialize ONS-5010 LYTENAVATM bevacizumab-vikg in China pursuant to a license agreement to be entered into between Outlook Therapeutics and the joint venture. 